Compare · EMBC vs SYK
EMBC vs SYK
Side-by-side comparison of Embecta Corp. (EMBC) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EMBC and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 307.8x EMBC ($365.5M).
- Over the past year, EMBC is down 55.5% and SYK is down 22.8% - SYK leads by 32.7 points.
- SYK has hit the wire 7 times in the past 4 weeks while EMBC has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 9 for EMBC).
- Company
- Embecta Corp.
- Stryker Corporation
- Price
- $6.29-2.56%
- $294.69+0.46%
- Market cap
- $365.5M
- $112.48B
- 1M return
- +21.22%
- +5.16%
- 1Y return
- -55.46%
- -22.78%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 7
- Recent ratings
- 9
- 25
Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest EMBC
- Director Morris Milton Mayo sold $36,971 worth of shares (6,293 units at $5.88), decreasing direct ownership by 10% to 53,828 units (SEC Form 4)
- SEC Form 144 filed by Embecta Corp.
- embecta to Participate in Investor Events
- Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.
- President and CEO Kurdikar Devdatt bought $140,937 worth of shares (30,000 units at $4.70), increasing direct ownership by 4% to 804,919 units (SEC Form 4)
- SVP and CFO Elguicze Jacob bought $93,360 worth of shares (20,000 units at $4.67), increasing direct ownership by 7% to 309,139 units (SEC Form 4)
- Pres, Pharm Svc&Prod Mgmt, CLO Mann Jeffrey Z bought $99,800 worth of shares (20,000 units at $4.99), increasing direct ownership by 8% to 262,915 units (SEC Form 4)
- Director Hombach Robert J. bought $223,848 worth of shares (45,000 units at $4.97), increasing direct ownership by 70% to 109,587 units (SEC Form 4)
- Chief Human Resources Officer Casner Jean covered exercise/tax liability with 1,480 shares, decreasing direct ownership by 2% to 85,915 units (SEC Form 4) (for tax liability)
- SEC Form S-8 filed by Embecta Corp.
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)